Zhejiang Yatai Pharmaceutical Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Zhejiang Asia Pacific Pharmaceutical Co., Ltd., formerly known as Zhejiang Asia Pacific Pharmaceutical Factory, was founded in 1989 and is currently located at 36 Nanbin West Road, Lihai Street, Yuecheng District, Shaoxing City, Zhejiang Province. The shareholding system transformation was completed in December 2001 and officially listed on the Shenzhen Stock Exchange on March 16, 2010 (stock code 002370). The company's factory covers a total area of over 120000 square meters. Currently, the company's products involve several major sectors such as chemical pharmaceutical preparations, chemical raw materials, and drug research and development. Ningbo Fubang Holding Group is a large private group that integrates commerce, real estate, energy, sports and other industries, and has been listed as a Fortune 500 enterprise over the years. On April 15, 2022, Fubon Group joined Asia Pacific Pharmaceutical as the controlling shareholder, and Asia Pacific Pharmaceutical became a member of Fubon Group's big health industry chain. Asia Pacific Pharmaceutical is a professional and large-scale national high-tech enterprise that integrates scientific research, production, and sales. The company has 8 modern pharmaceutical production workshops that meet national GMP standards, including tablets (including penicillin), hard capsules (including cephalosporins and penicillin), transdermal patches (hormones), freeze-dried powder injections, powder injections (cephalosporins), raw materials (azithromycin and roxithromycin), and has 106 drug approval numbers There are 2 approval numbers for raw materials, and 3 registration numbers for raw materials with a status of "A". At present, the company is a "National High tech Enterprise" and a "Zhejiang Province Industrial and Commercial Enterprise Credit A-level Contract abiding and Credit Valuing Unit". Asia Pacific Pharmaceutical has always adhered to the path of technological innovation in the development of new products. More than 20 technologies have obtained national patents, and it has a first-class quality testing center and drug research and development center in China. The company's drug research and development center is "Zhejiang Provincial Research Institute", "Zhejiang Provincial High tech Research and Development Center", "Zhejiang Provincial Enterprise Technology Center", and "Zhejiang Postdoctoral Research Workstation". The research and development team has been rated as "Zhejiang Provincial Innovation and Entrepreneurship Team". At the same time, with the technical support of China Pharmaceutical University, Shenyang Pharmaceutical University, Zhejiang University, and the Institute of Pharmacy of Zhejiang Academy of Medical Sciences, a professional and efficient new drug development team has been established, specializing in the research and development of transdermal controlled release systems, anti infection, cardiovascular, hypoglycemic, hepatitis and other drugs. The company always strictly controls quality during production, and currently has all passed the national GMP system certification. The company has always adhered to the promise of "integrity and win-win" in its operations, and has been rated as a trustworthy enterprise in Shaoxing City every year. It has also been awarded the title of "contract abiding and trustworthy" unit by the Zhejiang Provincial Administration for Industry and Commerce. At present, the products of Asia Pacific Pharmaceutical have covered various provinces, cities, and autonomous regions in China, with over 50 offices in various provinces across the country, and strive to be exported to multiple countries and regions. In the future, the company will continuously improve its product structure, strengthen the market, leverage its scientific research advantages, take the path of high-tech innovation and development, establish its brand image, and develop itself into a pharmaceutical enterprise with first-class competitiveness, creating a well-known brand in the Asia Pacific pharmaceutical industry. With first-class business philosophy and production management, we aim to create first-class products and create a well-known pharmaceutical brand that is trusted by the public, striving to achieve the cause of human health. |
| Headquarter | Shaoxing |
| Establish Date | 12/31/2001 |
| Listed Code | 002370.SZ |
| Listed Date | 3/16/2010 |
| Chairman | Song Lingjie. |
| CEO | Huang Xiaoming. |
| Website | www.ytyaoye.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
